[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypogonadal-males\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypogonadal-males":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100646720","assessment-of-effectiveness-of-pelvic-floor-muscle-training-with-biofeedback-in-male-with-hypogonadism-and-erectile-dysfunction-100646720",false,"NCT07687173","Assessment of Effectiveness of Pelvic Floor Muscle Training With Biofeedback in Male With Hypogonadism and Erectile Dysfunction","Assessment of Effectiveness of Pelvic Floor Muscle Training (PFMT) With Biofeedback in Male With Hypogonadism and Erectile Dysfunction (ED) a Randomised Control Trial.","Inclusion Criteria:\n\n* diagnosed functional hypogonadism\n* diagnosed erectile disorders\n* no diagnosed neurological disorders in pelvic floor area\n* no surgical interventions in pelvic floor area\n* no cancer in its active phase\n* ability to give individual consent\n* consent of participation and following the protocol\n\nExclusion Criteria:\n\n* severe cardiovascular diseases\n* cancer treatment in progress\n* scars and surgical interventions in the pelvic floor area\n* neurological disorders affecting to pelvic floor\n* scars that makes measurements impossible\n* other treatment that affects sexual field similar to this protocol\n* participation in other rehabilitation programme less than 6 months before this programme\n* severe neurological disorders that makes cooperation impossible\n* no technical possibilities to do the measures to the patient\n* disagreement to participate in the programme","MALE","18 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if Pelvic Floor Muscle Training (PFMT) with biofeedback works to treat Erectile Disorders (ED) in males with Functional Hipogonadism. The main hypothesis is:\n\n1\\. Biofeedback-assisted Pelvic Floor Muscle Training will cause greater improvement in pelvic floor muscle strength and endurance and sexual life than in group without biofeedback and control group in males with Erectile Disorders caused by functional hypogonadism.\n\nThe main questions it aims to answer are:\n\n1. Does biofeedback-assisted pelvic floor muscle training cause greater improvement in pelvic floor muscle strength and endurance and sexual life than in group without biofeedback and control group.\n2. Does using handheld biofeedback trainer device improves technique of Pelvic Floor Muscle Training performance compare to NO biofeedback.\n3. Does 12-week intervention cause greater improvement in analyzed parameters than 6-week intervention.\n4. Does participants using biofeedback will have greater adherence to training protocol than no biofeedback group.\n\nResearch will compare biofeedback-assisted Pelvic Floor Muscle Training to non-biofeedback Pelvic Floor Muscle Training and control group to see if Pelvic Floor Muscle Training works to treat Erectile Disorders in males with functional hypogonadism.\n\nParticipants will:\n\n1. Be measured using questionnaires and pelvic floor muscle electromyography\n2. Do Pelvic Floor Muscle Training for 12 weeks\n3. Provide a diary of their training routine\n4. Have repeated measurements in 6 and 12 weeks",[27,28,29,30,31,32],"Erectile Disfunction","Hypogonadal Males","Functional Hypogonadism","Pelvic Floor Muscle Exercise","Biofeedback Training","EMG",[34,35,29,36,37,38,39,40,41,32],"ED","Erectile Disoreders","Hyopogonadal males","Physiotherapy","PFMT","Pelvic Floor Muscles","Biofeedback","pelvic floor exercise","NOT_YET_RECRUITING","2026-07-03",{"date":45,"type":46},"2026-07-07","ACTUAL",{"date":48,"type":21},"2026-07-01",{"date":50,"type":21},"2029-06-01",{"name":52,"class":53},"Poznan University of Physical Education","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":54},"100632333","phase-2-effect-of-testosterone-on-elderly-frail-men-with-testosterone-deficiency-100632333","NCT07512323","Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency","Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency - a Double-blinded, Randomized and Placebo-controlled Intervention Study","Inclusion Criteria:\n\n* Men aged 70 or over.\n* Living at home in their own home or in sheltered housing.\n* Independent walking function, possibly with a walking aid.\n* Able to perform the chair-stand test a maximum of 8 times in 30 seconds or Timed Up and Go (TUG) of at least 30 seconds.\n* There must be at least 3 symptoms of frailty or objective findings.\n* Serum testosterone \\\u003C 10 nmol\u002FL as an average of 2 independent measurements at the Center for Growth and Reproduction, Rigshospitalet.\n\nExclusion Criteria:\n\n* Known or previous prostate cancer.\n* Abnormally elevated serum PSA (PSA = prostate-specific antigen) corresponding to PSA \\> 5 ng\u002Fml or PSA \\> 0.15 ng\u002Fml\u002Fcc (relative to prostate size in cubic centimeters (cc)).\n* Hemochromatosis.\n* Heart diseases in the form of: Peri-, myo-, or endocarditis, angina pectoris, severe heart failure (NYHA class III and IV), severe hypertension (systolic BP \\> 180 or diastolic BP \\> 105 mmHg after possible antihypertensive treatment). - Resting dyspnea.\n* Liver (ASAT \\> 2 x upper normal limit) or renal insufficiency (serum creatinine \\> 200 micromol\u002Fl).\n* Severe intractable epilepsy or migraine.\n* Insulin treatment.\n* Previous or current bisphosphonate, fluoride, HRT, SERM, strontium, teriparatide, or more than 3 weeks of prednisolone treatment.\n* Joint disease with acute inflammation.\n* Active cancer disease, in chemo- or radiotherapy.\n* Bone metabolic disease except for age-related osteoporosis.\n* Autoimmune diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure).\n* Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome (47,XXY), 46,XX males, LH resistance, Y chromosome deletions, other sex chromosome abnormalities.\n* Significant abuse, mental illness, dementia, physical handicaps with inability to complete the intervention or tests, or to give informed consent.\n* Contraindications for testosterone undecanoate are thus included in exclusion criteria, such as the presence of liver tumors, breast carcinoma, and prostate cancer, for which trial participants will be examined before the start of the trial.","70 Years",{"count":64,"type":21},96,[66],"PHASE2","The purpose of this study is to increase the functional level of the elderly to thereby reduce fall risk, improve motor skills, and increase psychological well-being, as well as to assess whether the restoration of a normal testosterone level contributes to a faster recovery. The effect of testosterone is investigated as measured by physical and mental functional capacity, including cognition, in hypogonadal elderly men with a significant loss of function. The study is aimed at participants who are too weak to participate in the progressive strength training.",[69,28,70,71],"Frail Elderly Patients","Testosterone Replacement Therapy","Falls (Accidents) in Old Age",[73,74,75,76],"hypogonadism","frailty","falls","testosterone replacement therapy","2026-04-29",{"date":79,"type":46},"2026-05-06",{"date":81,"type":21},"2026-08-01",{"date":83,"type":21},"2030-09-30",{"name":85,"class":53},"Rune Skovgaard Rasmussen"]